{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:36:11Z","timestamp":1760574971008,"version":"build-2065373602"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005297","name":"Uniwersytet Medyczny w Bialymstoku","doi-asserted-by":"publisher","award":["B.SUB.25.442"],"award-info":[{"award-number":["B.SUB.25.442"]}],"id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-025-05949-6","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T04:27:13Z","timestamp":1754972833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Friend or foe? Sebaceous cyst inflammation during ixekizumab therapy in psoriatic arthritis: case based review"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1537-7827","authenticated-orcid":false,"given":"Marta","family":"Ca\u0142us","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Grymuza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8018-9960","authenticated-orcid":false,"given":"Anna","family":"Baran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8173-9960","authenticated-orcid":false,"given":"Piotr","family":"My\u015bliwiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5923-910X","authenticated-orcid":false,"given":"Iwona","family":"Flisiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"5949_CR1","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1007\/s00296-024-05722-1","volume":"44","author":"D Boboryko","year":"2024","unstructured":"Boboryko D, Olejnik-Wojciechowska J, Baranowska M et al (2024) Biological therapy for psoriatic arthritis: current state and future perspectives. Rheumatol Int 44:2711\u20132725. https:\/\/doi.org\/10.1007\/s00296-024-05722-1","journal-title":"Rheumatol Int"},{"issue":"1","key":"5949_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/14712598.2018.1410133","volume":"18","author":"E Toussirot","year":"2018","unstructured":"Toussirot E (2018) Ixekizumab: an anti-IL-17A monoclonal antibody for the treatment of psoriatic arthritis. Expert Opin Biol Ther 18(1):101\u2013107. https:\/\/doi.org\/10.1080\/14712598.2018.1410133","journal-title":"Expert Opin Biol Ther"},{"key":"5949_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14486","author":"A Azhar","year":"2020","unstructured":"Azhar A, Zaayman M, Silfvast-Kaiser A, Kivelevitch D, Menter A, Paek SY (2020) Ixekizumab in the treatment of moderate\u2010to\u2010severe plaque psoriasis: patient adherence, satisfaction, and preferences. Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.14486","journal-title":"Dermatol Ther"},{"issue":"3","key":"5949_CR4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.4049\/jimmunol.1500909","volume":"195","author":"HR Conti","year":"2015","unstructured":"Conti HR, Gaffen SL (2015) IL-17-Mediated immunity to the opportunistic fungal pathogen Candida albicans. J Immunol 195(3):780\u2013788. https:\/\/doi.org\/10.4049\/jimmunol.1500909","journal-title":"J Immunol"},{"issue":"3","key":"5949_CR5","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1172\/JCI96481","volume":"128","author":"CA Dillen","year":"2018","unstructured":"Dillen CA, Pinsker BL, Marusina AI (2018) Clonally expanded \u03b3\u03b4 T cells protect against Staphylococcus aureus skin reinfection. J Clin Invest 128(3):1026\u20131042. https:\/\/doi.org\/10.1172\/JCI96481","journal-title":"J Clin Invest"},{"issue":"1","key":"5949_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/21501203.2023.2265664","volume":"15","author":"H Bilal","year":"2023","unstructured":"Bilal H, Khan MN, Khan S et al (2023) Risk of candidiasis associated with interleukin-17 inhibitors: implications and management. Mycology 15(1):30\u201344. https:\/\/doi.org\/10.1080\/21501203.2023.2265664","journal-title":"Mycology"},{"issue":"1","key":"5949_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jaad.2024.09.037","volume":"92","author":"Y Minami","year":"2025","unstructured":"Minami Y, Hiruma J, Harada K et al (2025) Risk of fungal infection in patients with psoriasis receiving biologics: A retrospective single-center cohort study. J Am Acad Dermatol 92(1):108\u2013115. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.037","journal-title":"J Am Acad Dermatol"},{"key":"5949_CR8","doi-asserted-by":"publisher","first-page":"1372693","DOI":"10.3389\/fimmu.2024.1372693","volume":"15","author":"S Khan","year":"2024","unstructured":"Khan S, Bilal H, Khan MN et al (2024) Interleukin inhibitors and the associated risk of candidiasis. Front Immunol 15:1372693. https:\/\/doi.org\/10.3389\/fimmu.2024.1372693","journal-title":"Front Immunol"},{"key":"5949_CR9","doi-asserted-by":"publisher","first-page":"100266","DOI":"10.1016\/j.lanepe.2021.100266","volume":"13","author":"L Davidson","year":"2022","unstructured":"Davidson L, van den Reek JMPA, Bruno M et al (2022) Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources. Lancet Reg Health\u2013 Europe 13:100266. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100266","journal-title":"Lancet Reg Health\u2013 Europe"},{"issue":"5","key":"5949_CR10","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/pde.14228","volume":"37","author":"M S\u00e1nchez Mart\u00edn","year":"2020","unstructured":"S\u00e1nchez Mart\u00edn M, Amores Hern\u00e1ndez I, Argum\u00e1nez Garc\u00eda D et al (2020) Staphylococcal toxic shock syndrome in a child with interleukin-17 inhibitor treatment for psoriasis. Pediatr Dermatol 37(5):952\u2013954. https:\/\/doi.org\/10.1111\/pde.14228","journal-title":"Pediatr Dermatol"},{"key":"5949_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2147\/CCID.S400679","volume":"16","author":"M Megna","year":"2023","unstructured":"Megna M, Battista T, Noto M et al (2023) Injections site reactions and biologics for psoriasis: a questionnaire-based real-life study. Clin Cosmet Investig Dermatol 16:553\u2013564. https:\/\/doi.org\/10.2147\/CCID.S400679","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"5949_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/ijd.14790","volume":"59","author":"E NicDhonncha","year":"2020","unstructured":"NicDhonncha E, Bennett M, Murphy LA, Murphy M, Bourke JF (2020) Injection site reactions to ixekizumab\u2013 a series of four patients. Int J Dermatol 59(5):137\u2013139. https:\/\/doi.org\/10.1111\/ijd.14790","journal-title":"Int J Dermatol"},{"issue":"5","key":"5949_CR13","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1080\/09546634.2022.2062281","volume":"33","author":"F Messina","year":"2022","unstructured":"Messina F, Piaserico S (2022) The dark side of the moon: the immune-mediated adverse events of IL-17A\/IL-17R Inhibition. J Dermatological Treat 33(5):2443\u20132454. https:\/\/doi.org\/10.1080\/09546634.2022.2062281","journal-title":"J Dermatological Treat"},{"key":"5949_CR14","doi-asserted-by":"publisher","first-page":"594735","DOI":"10.3389\/fimmu.2020.594735","volume":"11","author":"T Liu","year":"2020","unstructured":"Liu T, Li S, Ying S, Tang S, Ding Y, Li Y et al (2020) The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol 11:594735. https:\/\/doi.org\/10.3389\/fimmu.2020.594735","journal-title":"Front Immunol"},{"key":"5949_CR15","doi-asserted-by":"publisher","unstructured":"Chaitidis N, Papadopoulou Z, Varvara ST, Panagiotidis M, Katsigianni I, Sakellariou GT (2024) Paradoxical psoriasis induced by IL-17 inhibitors: a case series of patients with axial spondyloarthritis and a systematic literature review. Rheumatol Int 44(11):2659\u20132668. https:\/\/doi.org\/10.1007\/s00296-024-05647-9","DOI":"10.1007\/s00296-024-05647-9"},{"issue":"4","key":"5949_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/jdv.14622","volume":"32","author":"T Oiwa","year":"2018","unstructured":"Oiwa T, Honda T, Otsuka A, Kabashima K (2018) Three cases of facial erythema with dryness and pruritus in psoriasis patients during treatment with IL-17 inhibitors. J Eur Acad Dermatol Venereol 32(4):122\u2013123. https:\/\/doi.org\/10.1111\/jdv.14622","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5949_CR17","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1007\/s00405-024-08779-7","volume":"281","author":"L Maertens","year":"2024","unstructured":"Maertens L, Pollet N, Clarysse M et al (2024) Severely complicated ear infection in a patient treated with ixekizumab: a case report. Eur Arch Otorhinolaryngol 281:5549\u20135555. https:\/\/doi.org\/10.1007\/s00405-024-08779-7","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"5949_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12876-019-1067-0","volume":"19","author":"MK Smith","year":"2019","unstructured":"Smith MK, Pai J, Panaccione R, Beck P, Ferraz JG, Jijon H (2019) Crohn\u2019s-like disease in a patient exposed to anti-Interleukin-17 Blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report. BMC Gastroenterol 19:162. https:\/\/doi.org\/10.1186\/s12876-019-1067-0","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"5949_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.51821\/87.3.12874","volume":"87","author":"J Geldof","year":"2024","unstructured":"Geldof J, Truyens M, Strubbe B, Claeys S, Dewitte G, Glorieus E, Hoorens A, Lobaton T (2024) New onset inflammatory bowel disease after initiation of anti-IL-17a treatment: a case series. Acta Gastroenterol Belg 87(3):413\u2013417. https:\/\/doi.org\/10.51821\/87.3.12874","journal-title":"Acta Gastroenterol Belg"},{"issue":"5","key":"5949_CR20","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1007\/s10620-024-08380-2","volume":"69","author":"S Huynh","year":"2024","unstructured":"Huynh S, Achalu S, Berry R, Lin J, Wang CX, Gubatan J, Cheng AG (2024) Some drugs have two faces: paradoxical colitis in a patient with psoriatic arthritis previously treated with etanercept and IL-17 inhibitors. Dig Dis Sci 69(5):1602\u20131607. https:\/\/doi.org\/10.1007\/s10620-024-08380-2","journal-title":"Dig Dis Sci"},{"issue":"1","key":"5949_CR21","doi-asserted-by":"publisher","first-page":"2424338","DOI":"10.1080\/09546634.2024.2424338","volume":"35","author":"S Kaburaki","year":"2024","unstructured":"Kaburaki S, Okada N, Tanaka T, Kamio K, Tanaka Y, Terasaki Y et al (2024) Ixekizumab-induced interstitial lung disease: a case report confirmed by transbronchial lung cryobiopsy. J Dermatol Treat 35(1):2424338. https:\/\/doi.org\/10.1080\/09546634.2024.2424338","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"5949_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.12788\/cutis.0455","volume":"109","author":"J Pappas","year":"2022","unstructured":"Pappas J, Liaqat M, Halpern AV (2022) Severe acute systemic reaction after the first injections of Ixekizumab. Cutis 109(1):33\u201335. https:\/\/doi.org\/10.12788\/cutis.0455","journal-title":"Cutis"},{"issue":"8","key":"5949_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/rheumatology\/keab186","volume":"60","author":"MC McKenna","year":"2021","unstructured":"McKenna MC, Marnane M, Sheane BJ, Connolly S (2021) A case of multifocal motor neuropathy after initiation of Ixekizumab for psoriatic arthopathy. Rheumatology 60(8):282\u2013283. https:\/\/doi.org\/10.1093\/rheumatology\/keab186","journal-title":"Rheumatology"},{"key":"5949_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jdcr.2024.07.030","volume":"58","author":"S Balboul","year":"2024","unstructured":"Balboul S, Santiago S, Weston G, Lu J (2024) Hypopigmented mycosis fungoides-like eruption following Ixekizumab treatment. JAAD Case Rep 58:71\u201373. https:\/\/doi.org\/10.1016\/j.jdcr.2024.07.030","journal-title":"JAAD Case Rep"},{"issue":"1","key":"5949_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/ijd.ijd_719_24","volume":"70","author":"YK Ren","year":"2025","unstructured":"Ren YK, Ren L, Sun W, Liu HY, Guo SP (2025) Paradoxical beh\u00e7et\u2019s disease after ixekizumab: a case report and literature review. Indian J Dermatol 70(1):42\u201346. https:\/\/doi.org\/10.4103\/ijd.ijd_719_24","journal-title":"Indian J Dermatol"},{"key":"5949_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00296-025-05902-7","volume":"45","author":"N Chaitidis","year":"2025","unstructured":"Chaitidis N, Sakellariou GT, Daviti M et al (2025) Safety and efficacy of IL-17 inhibitors in patients with comorbid multiple sclerosis\/multiple Sclerosis-like syndrome: a systematic review. Rheumatol Int 45:147. https:\/\/doi.org\/10.1007\/s00296-025-05902-7","journal-title":"Rheumatol Int"},{"issue":"8","key":"5949_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/dj11080194","volume":"11","author":"K Irie","year":"2023","unstructured":"Irie K, Azuma T, Tomofuji T, Yamamoto T (2023) Exploring the role of IL-17A in oral dysbiosis-associated periodontitis and its correlation with systemic inflammatory disease. Dent J (Basel) 11(8):194. https:\/\/doi.org\/10.3390\/dj11080194","journal-title":"Dent J (Basel)"},{"issue":"2","key":"5949_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/14740338.2020.1709440","volume":"19","author":"L Puig","year":"2020","unstructured":"Puig L (2020) The safety of Ixekizumab in psoriasis drug therapy. Expert Opin Drug Saf 19(2):117\u2013130. https:\/\/doi.org\/10.1080\/14740338.2020.1709440","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"5949_CR29","doi-asserted-by":"publisher","first-page":"e0161759","DOI":"10.1371\/journal.pone.0161759","volume":"11","author":"AT Yuki","year":"2016","unstructured":"Yuki AT, Tobiishi M, Kusaka-Kikushima A, Ota Y, Tokura Y (2016) Impaired tight junctions in atopic dermatitis skin and in a skin-equivalent model treated with interleukin-17. PLoS One 11(9):e0161759. https:\/\/doi.org\/10.1371\/journal.pone.0161759","journal-title":"PLoS ONE"},{"issue":"15","key":"5949_CR30","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.3390\/ijms21155382","volume":"21","author":"BM Furue","year":"2020","unstructured":"Furue BM (2020) Regulation of filaggrin, loricrin, and involucrin by il-4, il-13, il-17a, il-22, ahr, and nrf2: pathogenic implications in atopic dermatitis. Int J Mol Sci 21(15):5382. https:\/\/doi.org\/10.3390\/ijms21155382","journal-title":"Int J Mol Sci"},{"issue":"16","key":"5949_CR31","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.3390\/molecules28166119","volume":"28","author":"CY Park","year":"2023","unstructured":"Park CY, Huddar S, Kim D (2023) Novel Quinazoline derivative induces differentiation of keratinocytes and enhances skin barrier functions against th2 cytokine-mediated signaling. Molecules 28(16):6119. https:\/\/doi.org\/10.3390\/molecules28166119","journal-title":"Molecules"},{"issue":"17","key":"5949_CR32","doi-asserted-by":"publisher","first-page":"9551","DOI":"10.3390\/ijms23179551","volume":"23","author":"DE Lee","year":"2022","unstructured":"Lee DE, Min K, Ahn H et al (2022) Potential therapeutic skin microbiomes suppressing Staphylococcus aureus-derived immune responses and upregulating skin barrier function-related genes via the Ahr signaling pathway. Int J Mol Sci 23(17):9551. https:\/\/doi.org\/10.3390\/ijms23179551","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5949_CR33","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1172\/jci40891","volume":"120","author":"EJ Cho","year":"2010","unstructured":"Cho EJ, Pietras E, Garcia N et al (2010) Il-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 120(5):1762\u20131773. https:\/\/doi.org\/10.1172\/jci40891","journal-title":"J Clin Invest"},{"issue":"6","key":"5949_CR34","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/ptr.6061","volume":"32","author":"FJ Lee","year":"2018","unstructured":"Lee FJ, Wu Q, Jang Y, Choung S (2018) Pinus densiflora bark extract ameliorates 2,4-dinitrochlorobenzene\u2010induced atopic dermatitis in nc\/nga mice by regulating th1\/th2 balance and skin barrier function. Phytother Res 32(6):1135\u20131143. https:\/\/doi.org\/10.1002\/ptr.6061","journal-title":"Phytother Res"},{"issue":"3","key":"5949_CR35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.chom.2019.02.002","volume":"25","author":"GF Sparber","year":"2019","unstructured":"Sparber GF, Gregorio C, Steckholzer S et al (2019) The skin commensal yeast malassezia triggers a type 17 response that coordinates anti-fungal immunity and exacerbates skin inflammation. Cell Host Microbe 25(3):389\u2013403e6. https:\/\/doi.org\/10.1016\/j.chom.2019.02.002","journal-title":"Cell Host Microbe"},{"issue":"6","key":"5949_CR36","doi-asserted-by":"publisher","first-page":"8863","DOI":"10.3892\/mmr.2017.7689","volume":"16","author":"HQ Tan","year":"2017","unstructured":"Tan HQ, Yang H, Liu E, Wang H (2017) P38\/erk Mapk signaling pathways are involved in the regulation of Filaggrin and involucrin by il-17. Mol Med Rep 16(6):8863\u20138867. https:\/\/doi.org\/10.3892\/mmr.2017.7689","journal-title":"Mol Med Rep"},{"issue":"2","key":"5949_CR37","doi-asserted-by":"publisher","first-page":"707","DOI":"10.4049\/jimmunol.1602185","volume":"199","author":"IA Floudas","year":"2017","unstructured":"Floudas IA, Saunders S, Moran T et al (2017) Il-17 receptor a maintains and protects the skin barrier to prevent allergic skin inflammation. J Immunol 199(2):707\u2013717. https:\/\/doi.org\/10.4049\/jimmunol.1602185","journal-title":"J Immunol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05949-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05949-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05949-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:15:02Z","timestamp":1760523302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05949-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["5949"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05949-6","relation":{},"ISSN":["1437-160X"],"issn-type":[{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marta Ca\u0142us, Julia Grymuza, Anna Baran, Piotr My\u015bliwiec, and Iwona Flisiak declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As this is a case-based review involving literature data and anonymized clinical information, ethical committee approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The patient signed informed consent regarding publishing their data and photographs.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"193"}}